According to the Hong Kong Stock Exchange's disclosure on December 15, Yiteng Pharmaceutical Group Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange and intends to be listed on the Hong Kong Main Board. Morgan Stanley Asia and Credit Suisse (Hong Kong) are limited co-sponsors.

The company is a comprehensive pharmaceutical company that strategically focuses on fighting infections, cardiovascular diseases and respiratory systems. According to Frost & Sullivan's report, these fields are the largest and fastest growing treatment fields. In 2020, anti-infection was the fourth largest treatment field in China, with a market size of 174.2 billion yuan, accounting for 12% of the entire Chinese pharmaceutical market. Cardiovascular disease is the third largest treatment field in China, with the highest disease burden. In 2020, the market size was 176.1 billion yuan. The respiratory system is one of the fastest growing emerging treatment areas. The market size in 2020 was 68.3 billion yuan, and is expected to increase at a compound annual growth rate of 13% in 2020 to 121.6 billion yuan in 2025.

The company's net profit for the 2019, 2020, and 2021 semi-years ending June 30 was 151 million yuan, 93.922 million yuan, and 269.43 million yuan respectively. The year-on-year changes were 219.93%, -37.98%, and 173.56%. (Data Treasure)

Note: This article is a news report and does not constitute investment advice. The stock market is risky, so you need to be careful when investing.